Table 5 The details of follow-up studies
Case no. | Surgery | Histopathology | Chemotherapy | ROS1 detection | CT imagine | TKI start time | Response | Reexamination CT imagine | Side effects |
|---|---|---|---|---|---|---|---|---|---|
Patient 3 | Video-assisted thoracic surgery (VATS) of the left upper lobe wedge resection | Invasive mucinous adenocarcinoma with pleural invasion | Pemetrexed, carboplatin | IHC, FISH and qRT-PCR had proved he as ROS1 rearrangement. Fusion type: CD74-E6 | The largest lesion in his left thoracic wall was approximate in size to 40.81 × 12.70 mm2 | Crizotinib 250 mg bid from December 2014 | February 2015, the lesion decreased to 26.66 × 11.69 mm2 in size | October 2015, the largest lesion shrunk to 10.85 × 8.60 mm2 in size | Tiredness and constipation |
Patient 6 | Lower right lobe radical resection; Biopsy under CT guidance | Invasive adenocarcinoma with acinar predominant pattern | Pematrexed, nadaplatin and bevacizumab | IHC, FISH and qRT-PCR had proved she as ROS1 rearrangement. Fusion type: CD74-E6 | The largest lesion was approximated in size to 36.25 × 36.25 mm2 on the pleura | Crizotinib 250 mg bid from April 2014 | May 2014, the largest lesion decreased to 11.02 × 8.59 mm2 in size | October 2015, the largest lesion shrunk to 10.48 × 10.33 mm2 in size | Edema in lower limbs, vomiting and tiredness |
Patient 7 | Biopsy under CT guidance | Invasive adenocarcinoma with acinar pattern | – | IHC and FISH had proved she as ROS1 rearrangement | The largest lesion was approximate in size to 35.33 × 19.73 mm2 | Crizotinib 250 mg bid from July 2014 | September 2014, the lesion decreased to 26.97 × 15.12 mm2 in size | November 2015, her largest lesion shrunk to 16.25 × 5.65 mm2 in size | Tiredness |